- Recalcitrant Pityriasis Rubra Pilaris Treated with Ustekinumab
-
Chae MH, Shin JY, Lee JY, Yoon TY
- KMID: 2440732
- Korean J Dermatol.
- 2019 Feb;57(2):101-102.
No abstract available. -
- CITED
-
- Close
- SHARE
-
- Close
- Paradoxical Flare of Psoriasis after Ustekinumab Therapy
-
Lee HY, Woo CH, Haw S
- KMID: 2395192
- Ann Dermatol.
- 2017 Dec;29(6):794-795.
- doi: 10.5021/ad.2017.29.6.794
No abstract available. -
- CITED
-
- Close
- SHARE
-
- Close
- The Phase 3 Trials of Ustekinumab as Induction and Maintenance Therapy for Crohn's Disease
-
Park SH
- KMID: 2383439
- Korean J Gastroenterol.
- 2017 Jan;69(1):90-91.
- doi: 10.4166/kjg.2017.69.1.90
No abstract available. -
- CITED
-
- Close
- SHARE
-
- Close
- Multiple Lentigines Arising in Sites of Resolving Psoriatic Plaques after Treatment with Ustekinumab
-
Kim JS, Lee SK, Ryu HR, Yun CH, Baek JO, Roh JY, Lee JR
- KMID: 2419186
- Ann Dermatol.
- 2018 Jun;30(3):371-372.
- doi: 10.5021/ad.2018.30.3.371
No abstract available. -
- CITED
-
- Close
- SHARE
-
- Close
- Squamous Cell Carcinoma Associated with Arsenic Keratosis in a Psoriasis Patient Treated with Ustekinumab: A Case Report
-
Jung SY
- KMID: 2391166
- Korean J Dermatol.
- 2017 Aug;55(7):440-444.
A 53-year-old Korean woman with known history of psoriasis and treatment with ustekinumab over 16 months, presented with a nontender erythematous plaque with oozing noted on her left sole. Histopathologic... -
- CITED
-
- Close
- SHARE
-
- Close
- Economic Burden Can Be the Major Determining Factor Resulting in Short-Term Intermittent and Repetitive Ustekinumab Treatment for Moderate-to-Severe Psoriasis
-
Choi CW, Choi JY, Kim BR, Youn SW
- KMID: 2414679
- Ann Dermatol.
- 2018 Apr;30(2):179-185.
- doi: 10.5021/ad.2018.30.2.179
BACKGROUND: The continuous use of biologic agents in the treatment of psoriasis has been reported to result in successful and sustained therapeutic effects and safety. However, some patients choose intermittent... -
- CITED
-
- Close
- SHARE
-
- Close
- Erythrodermic Psoriasis Improved by Ustekinumab: A Report of Two Cases
-
Kim YS, Kim HJ, Lee S, Park YL
- KMID: 2429497
- Ann Dermatol.
- 2016 Feb;28(1):121-122.
- doi: 10.5021/ad.2016.28.1.121
No abstract available. -
- CITED
-
- Close
- SHARE
-
- Close
- Economic Factors as Major Determinants of Ustekinumab Drug Survival of Patients with Chronic Plaque Psoriasis in Korea
-
Choi CW, Yang S, Jo G, Kim BR, Youn SW
- KMID: 2428922
- Ann Dermatol.
- 2018 Dec;30(6):668-675.
- doi: 10.5021/ad.2018.30.6.668
BACKGROUND: Drug survival, defined as the time until discontinuation, is a parameter reflecting real-world therapeutic effectiveness. Few studies have examined the influence of economic factors on the drug survival of... -
- CITED
-
- Close
- SHARE
-
- Close
- A Case of Paradoxical Flare of Pustular Psoriasis after Ustekinumab Therapy
-
Kang IH, Shin MK, Lee MH, Jeong KH
- KMID: 2436996
- Korean J Dermatol.
- 2018 Nov;56(9):548-551.
Biologics are the most advanced treatment for psoriasis. Ustekinumab, one of the biologics for psoriasis, is a human monoclonal antibody that binds to the p40 subunit of interleukin-12 and interleukin-23.... -
- CITED
-
- Close
- SHARE
-
- Close
- The Effect of Combination Treatment with Ustekinumab and Topical Agents in Korean Patients with Moderate-to-severe Psoriasis: A Retrospective Study of 30 Patients through 5 Years of Follow Up
-
Lim J, Woo Y, Kim M, Park HJ
- KMID: 2373099
- Korean J Dermatol.
- 2017 Mar;55(3):171-177.
BACKGROUND: Psoriasis is a chronic inflammatory skin disorder affecting approximately 1~3% of the general population. Ustekinumab is a recently developed human monoclonal antibody for psoriasis that binds to the p40... -
- CITED
-
- Close
- SHARE
-
- Close
- Ustekinumab is effective in biological refractory Crohn's disease patients–regardless of approval study selection criteria
-
Saman S, Goetz M, Wendler J, Malek NP, Wehkamp J, Klag T
- KMID: 2454742
- Intest Res.
- 2019 Jul;17(3):340-348.
- doi: 10.5217/ir.2019.00012
BACKGROUND/AIMS: Ustekinumab is effective in active Crohn's disease. In a retrospective study, we assessed the clinical outcome in nonresponders to anti-tumor necrosis factor therapy, and/or conventional therapy and/or the α4β7-integrin... -
- CITED
-
- Close
- SHARE
-
- Close
- Treatment Outcomes and Response Pattern of Ustekinumab in Korean Patients with Psoriasis: A Retrospective Single-center Study
-
Oh J, Kim T, Lee MG
- KMID: 2465951
- Korean J Dermatol.
- 2019 Sep;57(8):441-447.
BACKGROUND: Psoriasis is a chronic immune-mediated inflammatory skin disease affecting 2~3% of the worldwide population. Ustekinumab, an IL-12/23p40 inhibitor, is a biologic reported to be effective and safe in treating... -
- CITED
-
- Close
- SHARE
-
- Close
- Efficacy and safety of ustekinumab in Japanese patients with moderately to severely active Crohn's disease: a subpopulation analysis of phase 3 induction and maintenance studies
-
Hibi T, Imai Y, Murata Y, Matsushima N, Zheng R, Gasink C
- KMID: 2396397
- Intest Res.
- 2017 Oct;15(4):475-486.
- doi: 10.5217/ir.2017.15.4.475
BACKGROUND/AIMS: Efficacy and safety of ustekinumab were evaluated in a Japanese subpopulation with moderately to severely active Crohn's disease (CD) in UNITI-1, UNITI-2 and IM-UNITI studies and results were compared... -
- CITED
-
- Close
- SHARE
-
- Close
- Severe Nail Fold Psoriasis Extending from Nail Psoriasis Resolved with Ustekinumab: Suggestion of a Cytokine Overflow Theory in the Nail Unit
-
Byun SY, Kim BR, Choi JW, Youn SW
- KMID: 2429488
- Ann Dermatol.
- 2016 Feb;28(1):94-97.
- doi: 10.5021/ad.2016.28.1.94
Because nail psoriasis is difficult to treat, therapy with many biological drugs has been attempted. Ustekinumab is approved for chronic plaque psoriasis and psoriatic arthritis (PsA), with some trials reporting... -
- CITED
-
- Close
- SHARE
-
- Close
- Severe Refractory Atopic Dermatitis in an Adolescent Patient Successfully Treated with Ustekinumab
-
Agusti-Mejias A, Messeguer , Garcia R, Febrer I
- KMID: 2265881
- Ann Dermatol.
- 2013 Aug;25(3):368-370.
- doi: 10.5021/ad.2013.25.3.368
No abstract available. -
- CITED
-
- Close
- SHARE
-
- Close
- Efficacy and Safety of Ustekinumab in the Treatment of Moderate to Severe Psoriasis in Korea
-
Park SM, Kim JM, Kim GW, Mun JH, Song M, Kim HS, Ko HC, Kim MB, Kim BS
- KMID: 2245846
- Korean J Dermatol.
- 2015 Sep;53(8):617-622.
BACKGROUND: Ustekinumab, a fully human monoclonal immunoglobulin antibody that targets the P40 subunit shared by interleukin (IL)-12 and IL-23 has emerged as a promising treatment for moderate to severe psoriasis.... -
- CITED
-
- Close
- SHARE
-
- Close
- The MARCOPOLO Study of Ustekinumab Utilization and Efficacy in a Real-World Setting: Treatment of Patients with Plaque Psoriasis in Asia-Pacific Countries
-
Youn SW, Tsai TF, Theng C, Choon SE, Wiryadi BE, Pires A, Tan W, Lee MG, MARCOPOLO Investigators
- KMID: 2171381
- Ann Dermatol.
- 2016 Apr;28(2):222-231.
- doi: 10.5021/ad.2016.28.2.222
BACKGROUND: Ustekinumab is a fully human monoclonal antibody approved for the treatment of chronic moderate-to-severe plaque psoriasis in adults. However, factors including efficacy, tolerability, ease of use, and cost burden... -
- CITED
-
- Close
- SHARE
-
- Close
- Efficacy and Safety of Ustekinumab in Korean Patients with Moderate-to-severe Psoriasis
-
Kim KO, Lee SH, Lee SY, Whang KU, Park YL
- KMID: 2246084
- Korean J Dermatol.
- 2015 Jun;53(5):366-373.
BACKGROUND: Psoriasis is a chronic, relapsing inflammatory disease that affects approximately 2~3% of the population worldwide and often requires lifelong care. Recent advances in understanding the immunogenesis of psoriasis has... -
- CITED
-
- Close
- SHARE
-
- Close
- Appearance of Psoriasis after Tumor Necrosis Factor-alpha Blocker and Use of Ustekinumab or Tocilizumab for Refractory Monoarthritis
-
Moon J, Kwak N, Lim J, Go DJ, Lee JH, Park JK, Lee EB, Song YW, Youn JI, Lee EY
- KMID: 2222860
- J Rheum Dis.
- 2015 Aug;22(4):263-268.
- doi: 10.4078/jrd.2015.22.4.263
Nowadays, tumor necrosis factor-alpha (TNF-alpha) blockers are used for treatment of rheumatoid arthritis, inflammatory bowel diseases, ankylosing spondylitis, psoriatic arthritis, and psoriasis. Paradoxically, there are some reports on the appearance... -
- CITED
-
- Close
- SHARE
-
- Close
- The use of biologics for severe psoriasis
-
Youn SW
- KMID: 2195107
- J Korean Med Assoc.
- 2015 Oct;58(10):917-922.
- doi: 10.5124/jkma.2015.58.10.917
Psoriasis is a life-long chronic relapsing dermatosis that shows waxing and waning of disease despite of a lot of conventional treatment. Severe psoriasis, usually defined by a psoriasis area and... -
- CITED
-
- Close
- SHARE
-
- Close
